Protalix BioTherapeutics (PLX +6%) pops after the FDA accepts a resubmitted new drug application...

|About: Protalix BioTherapeutics, Inc (PLX)|By:, SA News Editor

Protalix BioTherapeutics (PLX +6%) pops after the FDA accepts a resubmitted new drug application for its experimental drug taliglucerase alfa, which is being developed to treat a rare genetic ailment called Gaucher's disease.